Study 903 Conclusions
No detectable tenofovir resistance (genotypic or phenotypic) in 22/29 (76%) TDF + 3TC + EFV failure patients
- no novel resistance patterns to TDF detected
- no patients developed TAMs
Effective second line regimens constructed in TDF-treated patients who developed K65R
- 5/7 patients achieved and maintained <50 copies/mL
- median follow-up 50 weeks on new regimen
- remaining patients lost to follow-up (n=1) or non-adherent (n=1)
Tenofovir DF + 3TC + EFV represents a simple and effective first line treatment option that preserves future treatment options